A Multi-center, Randomized, Double-blind, Active-controlled, Parallel-group Phase 3 Study to Evaluate the Efficacy and Safety of - Adventist HealthCare

Skip to Content

Clinical Trial Details

Paradise MI

A Multi-center, Randomized, Double-blind, Active-controlled, Parallel-group Phase 3 Study to Evaluate the Efficacy and Safety of LCZ696 Compared to Ramipril on Morbidity and Mortality in High Risk Patients Following an AMI

Purpose/Objective

Request Additional Trial Information
Full Trial Details: ClinicalTrials.gov

Condition: Acute Myocardial Infarction
Study Type: Interventional
Phase: N/A
Study Start Date: 12/09/2016
Study Completion Date: 07/17/2019

The purpose of this study is to test if LCZ696 taken twice a day, compared to Ramipril taken twice a day, is safe and effective in reducing complications following an acute myocardial infarction (post-AMI), such as death from cardiovascular (CV) causes, hospitalization for heart failure (HF), or outpatient HF.

NCT Number
NCT02924727
Principal Investigator(s)
Geetha Pinto, MD
Sponsor(s)
Novartis Pharmaceuticals
Participant Eligibility
  • Age: 18 - No Maximum
  • Gender: Male, Female

Location

  • Adventist HealthCare Shady Grove Medical Center
    9901 Medical Center Drive
    Rockville, MD 20850
    Main: 240-826-6000

Clincal Trials & Research Studies

Local Health News - In Your Inbox

Join over 100k of your friends & neighbors and get the latest news about community health programs and events when you sign-up for Adventist HealthCare & You Digital.

Subscribe Today!